Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies

AIMS: Veliparib is a potent inhibitor of poly(ADP‐ribose) polymerase (PARP) enzyme. The objectives of the analysis were to evaluate the effect of baseline covariates and co‐administration of topotecan plus carboplatin (T + C) on pharmacokinetics of veliparib in patients with refractory acute leukaem...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Clin Pharmacol
Главные авторы: Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gobburu, Jogarao, Greer, Jacqueline M., Piekarz, Richard, Karp, Judith E., Pratz, Keith, Rudek, Michelle A.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2017
Предметы:
Pharmacokinetics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5510066/
https://ncbi.nlm.nih.gov/pubmed/28156017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13253
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы